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Acute interaction between 
hydrocortisone and insulin alters 
the plasma metabolome in humans
Mohammad A. Alwashih ?ǡ ?ǡǤStimson ?ǡAndrew   ?ǡǤWalker ? &  
David G. Watson ?
With the aim of identifying biomarkers of glucocorticoid action and their relationship with biomarkers 
ǡƤ
who were administered either a low or medium dose insulin infusion (n = ? ?ȌǤǡ
ȋȌ+ /−ȋȌ
ǡǤ
ơȋȌȀ
ǡǤ

ǡơ
Ǥ
Ǥ
in vivo monitoring of 
glucocorticoid and insulin action.
Intracellular glucocorticoid receptors are widely expressed and afect energy metabolism, cardiovascular control 
and innate immunity1–5. Acute elevation in cortisol is a crucial component of the stress response, but chronic 
glucocorticoid excess (Cushing’s syndrome) causes obesity, type 2 diabetes, hypertension, impaired immunity, 
depression, and cognitive dysfunction. Common medical conditions such as type two diabetes and the meta-
bolic syndrome3 and neuropsychiatric disease4 are associated with mildly elevated circulating and tissue glu-
cocorticoid levels although at present it is not possible to measure circulating markers of tissue glucocorticoid 
action. Similarly, glucocorticoid deiciency, which can be life-threatening during stress, is especially diicult to 
diagnose during critical illness when conventional tests of cortisol production such as adrenocorticotrophic hor-
mone (ACTH) stimulation tests may be unreliable6. his lack of speciic biomarkers makes clinical manage-
ment of patients requiring glucocorticoid replacement therapy particularly challenging, and may contribute to 
well-documented excess morbidity and mortality in patients with hypopituitarism or adrenocortical failure7–10. 
he complexity of glucocorticoid action imposes a major limitation in the development of new therapeutic 
agents, because of the lack of reliable indicators of a reduction in tissue cortisol action.
Novel biomarkers of glucocorticoid action are urgently required and mass spectrometry has become increas-
ingly applied to this area. A previous study using gas chromatography with mass spectrometry (GC-MS) reported 
limited metabolomic proiling in urine and plasma of subjects treated with anti-inlammatory synthetic gluco-
corticoids11. A recent more comprehensive study was carried out using GC-MS and liquid chromatography-mass 
spectrometry (LC-MS) to both proile and quantify the metabolome of 20 healthy male volunteers following 
administration of the synthetic glucocorticoid dexamethasone12, which reduced plasma levels of alanine, methio-
nine, asparagine, phenylalanine, proline and serine.
Comparison of groups of people found a number of markers to be altered in insulin resistant individuals, 
particularly unsaturated fatty acids13. A distinct metabolic signature has been linked to obesity: elevated plasma 
levels of the branched chain amino acids (BCAs) leucine, isoleucine and valine; elevated amino acids methionine, 
glutamine, phenylalanine, tyrosine, asparagine, and arginine, with concomitant depression of glycine levels14; and 
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elevations of a number of free fatty acids and acyl carnitines. In fact, it has been proposed that BCA levels provide 
a better signature of metabolic health than BMI15 and may predict development of insulin resistance16.
To date, no direct study on the efects on insulin and cortisol on metabolic proiles in individuals has been 
reported. To identify biomarkers which relect glucocorticoid and insulin action, we performed metabolomic 
analysis of plasma samples obtained from a previously published study of healthy men treated with metyrapone 
followed by hydrocortisone (HC) infusion to induce low (~150 nM), medium (~400 nM) and high (~1400 nM, 
supra-physiological) circulating cortisol levels17. Moreover, we tested speciicity of the response to glucocorticoids 
by making measurements before and ater insulin infusion, and examined the interaction between insulin and 
HC.

Quality control. Metabolomic proiling of subjects was carried out by using LC-MS. A pooled plasma sam-
ple was prepared and the instrument was set to inject the pooled sample ater every 15 plasma samples, thus 
the pooled sample had 4 readings (Fig. 1). To quantify the precision of the measurements, the relative standard 
deviation (RSD) was calculated between the 4 pooled samples based on the sum of the intensities in each sample 
and an RSD of 0.5% was obtained. he RSD was also calculated for each of the metabolites in the pooled samples 
and the highest RSD was for 38:6 glycero-3-phosphoethanolamine (9.7%) while the lowest RSD was for alanine 
(0.23%). he precision of these values clearly indicates that any metabolomic diferences between groups could 
not be due to instrumental factors alone.
Data visualization. A hierarchical clustering analysis (Fig. 2) shows that samples almost clustered according 
to the insulin dose, group 3 consists of 32 samples, about 80% of the samples are for individuals receiving a high 
insulin dose. 100% of the observations in group 1, and also about 89% of the observations in group 2 are for indi-
viduals receiving a low insulin dose (Table 1). However, there were no signiicant diferences in HC dose between 
groups (Table 1). hus the HC doses did not show as large a contribution to the clustering pattern in comparison 
to the insulin dose.
Figure 1. 2D PCA score plot for QC (pooled) samples in healthy individuals. he plot shows the clustering of 
pooled samples (plum-QC) compared to the rest of plasma samples (grey-No class).
Figure 2. Hierarchical Clustering Analysis (HCA). he dendrogram above shows observations clustered into 
three groups. X-axis represents the samples and y-axis shows the similarity index. he higher the variability 
index the larger the between group variability and the lower the similarity index, the smaller the between group 
variability. he plot divides samples into three groups; group 1 (green), group 2 (blue) and group 3 (plum).
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A principal components analysis (PCA) score plot (Fig. 3A) showed separation between subjects having the 
highest insulin dose from those receiving a low insulin dose. However, subjects with the highest insulin dose also 
tended to show separation based on the HC dose. In addition, it is noticeable that subjects receiving a high HC 
dose overlap to some extent with the low insulin group and conversely there is some overlap between low HC and 
high insulin.
Separation between groups based on both insulin and HC dose can be seen more clearly in the OPLS-DA 
score plot (Fig. 3B), where the analysis is supervised, although subjects receiving medium and high HC dose 
showed some overlap where a low insulin dose was given.
ơǤ An OPLS-DA model was built on 606 fea-
tures, which were detected in 60 observations having either low or high insulin dose. Two observations (1M02 
and 2H10) were excluded as they were considered to be outliers based on Hotellings’T2 vs DModX plot, leaving 58 
observations (29 observations per group) from the high and low insulin groups. he resulting model identiied 31 
putative biomarkers (Table 2) which were selected based on their 95% conidence interval of diference (CI), cor-
rected p-values ( < 0.05), and the AUC of their ROC curves ( > 0.7). hese metabolites were then used to rebuild 
the OPLS-DA model (Fig. 4) in order to examine its ability to separate the subjects based on the insulin dose.
he OPLS-DA score plot (Fig. 4) showed clear separation between the two groups; around 79% of the varia-
bility in metabolites was explained by the model, of which 57% was due to insulin dose alone with the rest being 
attributable to systemic or orthogonal variations. 84% of the variability between the observations was explained 
by the variability in the metabolites, of which 80% was predicted by the model following cross-validation. he 
HCA grouping Observations (n)
Percentage in each group (%)
Low Insulin High Insulin
Low HC Medium HC High HC Low HC Medium HC High HC
1 (Green) 7 28.6 28.6 42.9 0.0 0.0 0.0
2 (Blue) 17 23.5 29.4 35.3 0.0 0.0 11.8
3 (Plum) 32 9.4 6.3 3.1 28.1 31.3 21.9
Table 1. Proportions of HC and insulin doses based on the HCA grouping.
Figure 3. (A, let) PCA vs (B, right) OPLS-DA score plots for healthy individuals receiving diferent doses of 
HC and insulin. PCA score plot (A) includes 2 groups of subjects (n = 30 samples/10 subjects/group). Group 
1 denotes samples with low insulin dose (n = 30), group 2 denotes samples with high insulin dose (n = 30). 
Subjects in each group have 3 diferent levels of HC treatment; L = low HC, M = medium HC and H = high HC 
dose. OPLS-DA score plot (B) includes the same group of subjects. Subjects in the same oval shapes were given 
the same insulin dose. In the OPLS-DA, model separation is between low and high HC doses in each insulin 
group but the domain of the medium HC dose overlaps with that of high HC dose in both insulin groups, while 
in the high insulin group also overlaps with the low GC dose.
www.nature.com/scientificreports/
4SCIENTIFIC REPORTSȁ ?ǣ 11488 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
validity of the number of orthogonal components in the model was examined using observed versus predicted 
plot. he regression line in the plot had R2 = 0.84 (Figure S1A, supplementary) indicating acceptable model valid-
ity. Based on a permutation test (Figure S1B, supplementary) this model had a valid predictive ability compared to 
the newly permuted Q2 values. Using 31 putative metabolites that were signiicantly changed by the insulin dose 
it was possible to classify 100% of the observations based on the insulin dose (Figure S2).
Table 2 shows that all the marker metabolites were signiicantly decreased (p < 0.05) at high compared to 
low insulin doses except for indolepyruvate which was signiicantly increased (p = 0.008). he majority of these 
metabolites demonstrated excellent classifying ability based on their AUC values (AUC > 0.9). Of the metabolites 
which were separated on the C18 column, only 3-Methyl-2-oxopentanoic acid was signiicantly afected (H/L 
ratio = 0.71; p = 0.001) although it only had a moderate classifying ability (AUC = 0.77)18.
Generally, in order to avoid the possibility of over-itting in an OPLS-DA model, the number of the variables 
should be less than the total number of observations. Xia et al. suggested that using 1–10 biomarkers for classi-
ication is more statistically robust and clinically more practical18. An OPLS-DA model (Fig. 5) was built on 10 
variables having the highest AUC values among the metabolites signiicantly afected by the insulin dose (Table 3) 
in plasma samples of 58 subjects (low insulin = 29, high insulin = 29). All these metabolites were strongly neg-
atively correlated to insulin dose (|r| > 0.88). Two observations (1M02 and 2M12) were excluded as they were 
strong outliers based on Hotelling’sT2 vs DModX plot. he model shows that approximately 93% of the variations 
in these putative biomarkers were explained by the model; 82% of this variation was due to the insulin dose with 
P CV-ANOVA = 4.91E-12, while approximately 12% was due to inter-individual variability. he AUC shows an 
excellent ability of these metabolites to classify 98% of the subjects based on insulin dose using 10 biomarkers.
Metabolite AUC High insulin/Low insulin p-value
Polyunsaturated fatty acids
C22:4 0.87 0.48 0.0001
C22:6 0.86 0.46 0.0001
C20:2 0.92 0.37 0.000005
C20:4 0.81 0.59 0.002
C18:2 0.94 0.29 6.38E-07
C18:3 0.94 0.27 0.000002
Monounsaturated fatty acids
C20:1 0.97 0.26 4.40E-07
C18:1 0.94 0.30 0.000003
C16:1 0.95 0.23 6.68E-07
C14:1 0.90 0.32 0.00001
Straight chain fatty acids
C20:0 0.86 0.53 0.0001
C17:0 0.88 0.44 0.00001
C16:0 0.92 0.36 0.000007
C15:0 0.88 0.45 0.0001
C14:0 0.89 0.35 0.00002
C10:0 0.84 0.60 0.001
Acyl carnitines
O-Acetylcarnitine* 0.92 0.57 4.60E-07
Decanoylcarnitine 0.91 0.47 0.000002
Oleoylcarnitine 0.96 0.58 0.000007
Branched chain amino acids
L-Leucine* 0.79 0.74 0.003
3-Methyl-2-oxopentanoic acidC18 0.77 0.71 0.001
4-Methyl-2-oxopentanoate* 0.75 0.67 0.003
L-Isoleucine* 0.82 0.76 0.00008
L-Valine* 0.77 0.85 0.021
Miscellaneous
Hydroxybutanoic acid 0.93 0.28 0.00006
2-Hydroxybutanoic acid* 0.73 0.64 0.013
Indolepyruvate 0.79 1.34 0.008
Gamma-Glutamylglutamine 0.73 0.81 0.017
Glycerol 0.90 0.74 0.0001
Table 2. Metabolites signiicantly altered by insulin dose. *Retention time conirmed by standard. C18 
metabolites identiied using C18-AR column, the rest identiied using ZICpHILIC column. (L = low insulin 
dose, H = high insulin dose), p-value is an output of split-plot ANOVA.
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Figure 4. OPLS-DA score plot for healthy individuals having either high or low insulin dose. he OPLS-DA 
score plot shows two groups of samples (n = 29 samples per group) based on readings of 29 signiicant 
metabolites in plasma of healthy individuals. Subjects with low insulin dose (green) and subjects with high 
insulin dose (blue). he model consists of one predictive x-score component; component t[1] and one 
orthogonal x-score components to[1]. t[1] explains 56.9% of the predictive variation in x, to[1] explains 22% of 
the orthogonal variation in x, R2X (cum) = 0.789, R2Y (cum) = 1, R2 (cum) = 0.841, Accuracy of prediction Q2 
(cum) = 0.796.
Figure 5. OPLS-DA score plot for the efect of insulin on 10 selected metabolites. he OPLS-DA score plot 
based on 10 most signiicant metabolites showing two groups: samples with low insulin dose (green) and 
samples with high insulin dose (blue). he model consists of one predictive x-score component; component t[1] 
and one orthogonal x-score components to[1]. t[1] explains 82% of the predictive variation in x, to[1] explains 
11.2% of the orthogonal variation in x, R2X (cum) = 1, R2Y (cum) = 1, R2 (cum) = 0.706. Accuracy of prediction 
Q2 (cum) = 0.665.
Putative biomarkers r 99% CI of diference
C20:2 −0.88 (−0.301, −0.227)
C18:3 −0.92 (−0.297, −0.254)
C18:2 −0.92 (−0.3, −0.254)
C18:1 −0.94 (−0.304, −0.259)
C16:1 −0.92 (−0.285, −0.267)
C20:1 −0.94 (−0.318, −0.25)
Hydroxybutanoic acid −0.83 (−0.316, −0.181)
Palmitic acid −0.89 (−0.3, −0.234)
O-Acetylcarnitine −0.88 (−0.33, −0.194)
Oleoylcarnitine −0.94 (−0.367, −0.198)
Table 3. he 10 metabolites with highest AUC values and their correlations (r) to insulin dose.
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ơǤ A total of 606 putative biomarkers were meas-
ured in 60 subjects receiving 3 diferent HC doses: low HC dose = 20 subjects, medium dose = 20 subjects and 
high dose = 20 subjects. 4 observations (1L02, 1M02, 2L04 and 2H06) were excluded as they were considered 
to be outliers based on Hotellings’T2 vs DModX plot. he medium HC dose was found to be a poorly classiied 
by the biomarkers having AUC of 0.67 compared to low and high HC dose (AUC = both 1.0), and thus had a 
high proportion of misclassiied observations (47.4%) compared to the other two doses (0% each) (Table S1, 
supplementary). In addition, this dose was found to overlap with both low and high doses (Fig. 3). herefore, 
the medium HC dose was not considered for further comparisons and in subsequent analyses and comparisons 
between low HC vs high HC were used to determine how HC dose afects the human plasma metabolome.
In a comparison of low HC vs high HC, 23 putative biomarkers (Table S2) passed the 95% CI ilter and showed 
signiicant change based on FDR corrected p values, and had an AUC above 0.7. hese 23 putative biomarkers 
were used to rebuild an OPLS-DA model (Figure S3, supplementary) in order to examine its ability to separate 
observations based on HC dose. he igure shows separation between observations having either low or high HC 
doses. Approximately 66% of the variability in metabolites was explained by the model, of which 38.5% was due to 
HC dose alone with the rest being attributable to other factors related to inter-individual variability. he result for 
the cross-validation of the model is shown in Figure S4. he validity of the number of orthogonal components in 
the model was examined using an observed versus predicted plot (Figure S4A), the regression line R2 = 0.82 indi-
cates a valid model. According to the area under the ROC curve, 23 putative biomarkers that were signiicantly 
changed by the HC dose were 100% successful in classifying the observations (Figure S5). here was a signiicant 
elevation of branched chain amino acids and their deaminated metabolites ater the highest HC dosage (Table S2, 
supplementary). Purine metabolites, represented by xanthine and hypoxanthine, and C20:4, C22:6 and C18:3 
acids, were signiicantly elevated by the highest HC dose. On the other hand, the steroids pregnenolone sulfate 
and androsterone glucuronide were the only metabolites that showed signiicant reduction ater the highest HC 
dose.
In order to reduce any danger of overitting a further OPLS-DA model (Fig. 6) was built on the 10 variables 
having the highest AUC values among the metabolites signiicantly afected by the HC dose (Table 4) in plasma 
samples of 38 subjects (low = 19, high = 19). All these metabolites showed varying degrees of positive correla-
tion (0.54 ≤ r ≤ 0.85) except for the steroid conjugates androsterone glucuronide (|r| = 0.7) and pregnenolone 
sulfate (|r| = 0.85) which were negatively correlated with HC dose. he model shows that about 66% of the var-
iations in these biomarkers were explained by the model, 50% of this variation was due to the HC dose with P 
CV-ANOVA = 4.32E-08, while about 16% was due to orthogonal variation. he area under the ROC indicated an 
excellent ability of these metabolites to classify 100% of the observations based on HC dose.
ơǤ Twelve metabolites were found to be sig-
niicantly altered by both insulin and HC treatments (p < 0.05) as shown in Table 5.
All of the 12 metabolites were elevated by HC and reduced by insulin doses respectively. A heat map of the 12 
metabolites which were signiicant in both interventions was plotted using Metaboanalyst based on intensities 
of each metabolite in each observation (Figure S6). he clearest efect that can be seen in the heat map is that the 
metabolites reduced in observations with a high dose of insulin plus low dose of HC were elevated in the samples 
with low insulin plus high HC doses. In addition, individuals responded diferently with regard to these metabo-
lites when high insulin and high HC or low insulin and low HC were given.
Figure 6. OPLS-DA score plot for the efect of HC dose on 10 signiicant putative metabolites with highest 
AUC values in plasma of healthy individuals. he plot shows two groups: subjects with low HC dose (grey-blue) 
and subjects with high HC dose (red). he model consists of one predictive x-score component; component t[1] 
and one orthogonal x-score components to[1]. t[1] explains 50% of the predictive variation in x, to[1] explains 
15.8% of the orthogonal variation in x, R2X (cum) = 0.65.9, R2Y (cum) = 1, R2 (cum) = 0.74 and accuracy of 
prediction Q2 (cum) = 0.693.
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Based on split-plot ANOVA, only three metabolites (Table 6) showed signiicant interaction between insulin 
and hydrocortisone doses. All the three metabolites were signiicantly increased (p < 0.05) by HC dose but only 
one of them, 3-methyl-2-oxobutanoic acid, was signiicantly decreased (p = 0.036) by high insulin dose.
Discussion
he clearest efect where insulin and hydrocortisone oppose each other is with regard to an efect on the metab-
olism of branched chain amino acids and their metabolites. High insulin signiicantly reduces the levels of leu-
cine/isoleucine, valine (branched chain amino acids, BCAs) and their metabolites compared with low insulin 
(Example chromatograms shown in Figure S7). Increasing the level of HC infusion increases the levels of leucine/
isoleucine and their metabolites irrespective of insulin dose. HC in the presence of the low insulin infusion also 
produces an increase in BCAs as the concentration of HC is increased and this is the strongest metabolic signa-
ture of HC action amongst all the signiicantly altered metabolites. his observation links to the role of BCAs in 
obesity and insulin resistance observed in the literature14–16. hus, in the current case, a similar efect is observed 
from a diferent perspective, where insulin directly lowers BCA levels signiicantly and HC opposes this efect. 
HC is known to promote breakdown of muscle proteins19, while BCAs are known to promote production of 
muscle protein20–22. Insulin is known to promote production of muscle tissue and this would be consistent with 
an increased requirement for BCAs and hence a reduction of their circulating levels. BCAs may exert some ben-
eicial efect in the treatment of insulin resistance associated with chronic liver disease. In a rat model with liver 
cirrhosis, BCAs improved glucose uptake23; in rodents, BCAs improve glucose metabolism in hepatocytes, skel-
etal muscle, and adipocytes24–26.
We previously reported that free fatty acids were increased by high cortisol17, this current work highlights this 
efect with regards to poly unsaturated fatty acid (PUFA) metabolism and is in opposition to the efect of insulin. 
Previously it was observed that omega-3/omega-6 PUFA levels increased in response to BCAs in two cases26, 27. In 
the current case, high insulin lowers the levels of PUFA and, irrespective of insulin, the highest HC dose increases 
levels of PUFA.
he most comprehensive list of metabolites within a class that were afected by insulin are the free fatty acids 
(FFAs). Many FFAs are lowered by >  × 2 by insulin infusion and efects are seen on fatty acids with chain lengths 
between C10 and C22. HC appears to act in an opposite manner to insulin by promoting higher levels of some 
FFAs in plasma. Presumably a relatively low level of HC is required to increase levels of FFAs and thus increasing 
the level of the HC infusion does not promote this process any further—a reason why there was no signiicant 
diference between medium and high HC doses. Nevertheless, irrespective of insulin, which lowers the levels of 
FFAs, the efect on some fatty acids of increasing the level of HC in the infusion can be observed.
Batch et al. also described the elevation of C3 and C5 acylcarnitines in obese compared with lean subjects and 
the elevation of these metabolites in rats fed a diet enriched with BCAs14. Insulin has a marked efect in lowering 
acyl carnitines. he most marked efect is in lowering decanoylcarnitine. HC does not have a marked efect on 
the levels of these metabolites, signiicantly increases the level of 2-methylbutyrylcarnitine. High HC also pro-
motes a marked elevation of oleoylcarnitine. here is evidence that high levels of long chain fatty acids are toxic, 
promoting apoptosis via a mechanism involving caspase 228. Carnitine conjugation provides a means removing 
fatty acids from tissues29.
Tryptophan metabolism is regulated by glucocorticoids and insulin which regulate the enzyme tryptophan 
dioxygenase (TDO)30–33. Indolepyruvate as a metabolite in the tryptophan pathway shows signiicant elevation 
following high insulin dose and non-signiicant reduction following HC dose. Bordag et al. observed elevation 
of a number of tryptophan metabolites in plasma following dexamethasone treatment12. here is a link between 
tryptophan metabolism via the kynurenine pathway and purine metabolism. TDO has haem at its active centre 
and enzyme activity is regenerated by coupling with the superoxide anion. One of the major sources of superox-
ide in the body is from the action of xanthine oxidise which converts hypoxanthine via xanthine to uric acid34. 
Elevated xanthine and hypoxanthine are associated with the high HC group and this could indicate an increase in 
xanthine oxidase leading to increased availability of the superoxide required to support TDO activity33.
Finally, the other major alterations in response to HC are, as might be expected, in steroid metabolism. HC 
suppresses ACTH resulting in reduced adrenocortical secretion of precursor steroids which, in the presence of 
Putative biomarkers r 99% CI of diference
(S)-3-Methyl-2-oxopentanoic acidC18 0.78 (0.159, 0.403)
4-Methyl-2-oxopentanoate* 0.85 (0.193, 0.418)
L-Isoleucine* 0.69 (0.118, 0.381)
Methylacetoacetic acid 0.56 (0.021, 0.381)
2-Hydroxybutanoic acid* 0.68 (0.082, 0.408)
2-Ketobutyric acid* 0.54 (0.045, 0.344)
2-Methylbutyroylcarnitine 0.66 (0.04, 0.436)
Xanthine* 0.68 (0.0025, 0.488)
Androsterone glucuronide −0.7 (−0.418, −0.088)
Pregnenolone sulfate −0.85 (−0.422, −0.192)
Table 4. he 10 metabolites with highest AUC values and their correlations (r) to HC dose. *Retention time 
conirmed by standard.
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metyrapone, are diverted to adrenal androgens. his likely explains the reduction, with increasing HC, of andros-
terone glucuronide, a metabolite of adrenal androgens such as dehydroepiandrosterone, dihydrotestosterone or 
androstenedione; and of pregnenolone sulphate, a metabolic precursor of HC.
Of course, metabolite changes detected in plasma are only an indirect indicator of the biochemical changes in 
target tissues for cortisol and insulin. he current study is limited to acute manipulations of insulin and cortisol, 
and may not be replicated with longer term manipulations. In these studies, a ‘pancreatic clamp’ was employed, 
involving infusion of somatostatin and replacement with glucagon and growth hormone in addition to insulin 
infusion; diferent efects of insulin and cortisol might have been observed in the absence of the pancreatic clamp. 
Moreover, there may be a bias in metabolomic studies in favour of detecting changes in the most abundant, 
rather than the most biologically important metabolites. Of equal interest, however, is the pragmatic application 
of changes in metabolites as biomarkers to measure glucocorticoid or insulin action. For insulin, fasting plasma 
insulin/glucose ratios are the only non-invasive approach to determine insulin sensitivity, and classiication of 
risk of type 2 diabetes could be enhanced by additional biomarkers. By combining 10 markers, we demonstrate 
high sensitivity to discriminate between high dose and low dose insulin infusion, but further tests in larger num-
bers will be required to test associations with physiological insulin action. For glucocorticoids, there are no reli-
able speciic or sensitive biomarkers, since even measurement of plasma cortisol is subject to many caveats. We 
show that a combination of 10 markers has moderately high sensitivity to discriminate between low and high dose 
HC infusion, although the discrimination of medium dose infusion remained relatively poor (AUC = 0.69). In 
related work it was found that 7 marker compounds were predictive of corticosteroid dose in patients with con-
genital adrenal hyperplasia undergoing hormone replacement therapy (paper submitted). It remains to be tested 
whether the markers discovered in the current study, in combination or alone, will be sensitive to physiological 
or pharmacological variation in cortisol action, and crucially whether they have speciicity when compared with 
efects of obesity and other features which accompany glucocorticoid excess.
Materials and Methods
Ǥ HPLC grade acetonitrile (ACN) was purchased from Fisher Scientiic, UK. 
HPLC grade water was produced by a Direct-Q 3 Ultrapure Water System from Millipore, UK. AnalaR grade 
formic acid (98%) was obtained from BDH-Merck, UK. Ammonium carbonate and ammonium acetate were 
purchased from Sigma-Aldrich, UK.
Sample collection. he study protocol has been described in detail previously17. In brief, 20 healthy men 
(age 33.4 ± 3.5 years, BMI 23.8 ± 03 kg/m2) were recruited to a randomised crossover study. Written informed 
consent was obtained from each participant as well as approval from the South East Scotland Research Ethics 
Putative metabolite 1 L: 1 H: 2 L: 2 H p-value (HC) p-value (insulin)
Fatty acids
C20:4 1: 1.34: 0.54: 0.84 0.002 0.002
C22:6 1: 1.44: 0.38: 0.75 0.000289 0.000126
C18:0 1: 1.36: 0.42: 0.71 0.005 0.00002
C17:0 1: 1.37: 0.37: 0.67 0.005 0.000015
C20:0 1: 1.26: 0.41: 0.79 0.001 0.000106
2-Hydroxybutanoic acid* 1: 1.63: 0.62: 1.07 0.000013 0.013
Branched chain amino acids
L-Isoleucine* 1: 1.23: 0.69: 0.98 0.000058 0.000089
L-Leucine* 1: 1.25: 0.77: 0.95 0.002 0.003
L-Valine* 1: 1.18: 0.86: 0.99 0.001 0.021
4-Methyl-2-oxopentanoate* 1: 1.62: 0.62: 1.13 0.0018 0.003
(S)-3-Methyl-2-oxopentanoic acid C18 1: 1.57: 0.71: 1.11 0.000000061 0.001
Peptide
Gamma-Glutamylglutamine 1: 1.19: 0.79: 0.98 0.004 0.017
Table 5. Metabolites signiicantly afected by both interventions. *Retention time conirmed by standard. 
C18metabolites identiied using C18-AR column, the rest identiied using ZICpHILIC column. (in the ratio 
column, 1 = low insulin, 2 = high insulin, L = low hydrocortisone, H = high hydrocortisone).
Putative metabolite
Ratio P-value
1 L: 1 H: 2 L: 2 H Interaction Hydrocortisone Insulin
2-methylbutyrylcarnitine 1: 1.9: 1.07: 1.38 0.015 0.000008 0.369
Methylacetoacetic acid 1: 1.4: 0.94: 1.04 0.023 0.000272 0.086
3-Methyl-2-oxobutanoic acid 1: 1.3: 0.94: 1.02 0.014 0.000364 0.036
Table 6. Metabolites that showed signiicant interaction in both interventions. In the ratio column, 1 = low 
insulin, 2 = high insulin, L = low HC, H = high HC.
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Committee (reference number 09/S1102/50). All the experimental protocols were carried out in accordance with 
the relevant guidelines and regulations concerning the participation of human subjects. Eligibility criteria were 
as follows: body mass index 20–25 kg/m2; normal screening blood tests (full blood count, glucose, liver, renal 
and thyroid function); alcohol intake ≤ 21 units/week; no medical conditions or on any regular medications; no 
glucocorticoid therapy by any route in the previous 12 months; weight of of < 5% in the past 6 months. Subjects 
attended for three study days ater overnight fast. Subjects were randomised to receive either low dose (0.06 
mU/kg/min) or medium dose (0.2 mU/kg/min) insulin infusion (both groups n = 10) on all three occasions 
for 6 hours. In addition, intravenous infusions of dextrose, 6,6-2H2-glucose, 1,1,2,3,3-
2H5-glycerol, somatosta-
tin, glucagon and growth hormone were commenced. he three study days were separated by at least 3 weeks 
and comprised, in random order, ‘low’, ‘medium’ and ‘high’ glucocorticoid phases: subjects all received 1 gram 
of metyrapone orally at 2300 h the night before each assessment and at 0700 h and 1100 h to suppress endoge-
nous adrenal cortisol production; for the low glucocorticoid phase subjects took placebo tablets at 2300 h and 
0700 h and were infused with saline to achieve plasma cortisol concentrations of ~150 nM; for the medium glu-
cocorticoid phase, subjects took hydrocortisone 10 mg orally at 2300 h and 5 mg at 0700 h and were infused with 
hydrocortisone 0.04 mg/kg bolus followed by 0.025 mg/kg/h to achieve plasma cortisol levels of ~400 nM; for 
the high glucocorticoid phase subjects took hydrocortisone 20 mg orally at 2300 h and 10 mg at 0700 h and were 
infused with hydrocortisone 0.18 mg/kg/h bolus and 0.12 mg/kg/h to achieve plasma cortisol concentrations of 
~1400 nM17. Samples for metabolomics analysis were obtained ater 4 hours of the protocol.
Sample preparation. Plasma samples were stored at −30 °C and thawed at room temperature prior to 
preparation for LC-MS analysis. For analysis using ZIC-pHILIC conditions, 200 µl of plasma was thoroughly 
mixed with 800 µl of acetonitrile, followed by centrifugation at 3000 revolutions per minute (RPM) for 5 minutes; 
800 µl of supernatant was then transferred to a LC vial. For the RP conditions, 200 µl of plasma was diluted with 
800 µl of acetonitrile and followed by centrifugation at 3000 revolutions per minute (RPM) for 5 minutes.
ǦǤ Samples were randomly placed in the autosampler tray and the LC-MS experi-
ment was performed on an Accela 600 HPLC system combined with an Exactive (Orbitrap) mass spectrometer 
from hermo Fisher Scientiic (Hemel Hempstead, UK). In separate runs, 10 µL of sample was injected onto two 
columns obtained from HiChrom Ltd., Reading, UK: a ZIC-pHILIC column (150 × 4.6 mm, 5 µm particle) and 
an ACE C18-AR column (150 × 4.6 mm, 5 µm particles). he LC–MS system was run in binary gradient mode. 
A low rate of 0.3 mL/min was used and samples were kept in a vial tray set at 3 °C. he mobile phase conditions 
were as follows: (i) ZIC-pHILIC: A 20 mM ammonium carbonate pH 9.2 B Acetonitrile; 0 min 80% B 30 min 
20% B, 36 min 20% B, 37 min 80% B, 46 min. 80% B. (ii) C18 AR: A 0.1% v/v formic acid in water, B 0.1% v/v 
formic acid in acetonitrile; 0 min. 5% B 30 min 95% B 36 min 95% B 37 min 5% B 46 min 5% B. he ESI interface 
was operated in positive and negative ion switching mode, with + 4.0 kV of spray voltage for positive mode and 
−3.5 kV for negative mode. he temperature of the ion transfer capillary was 270 °C and sheath and auxiliary gas 
were set at 57 and 17 arbitrary units, respectively. he full scan range of both positive and negative modes was set 
at 75 to 1200 m/z with AGC target and resolution as Balanced and High (1E6 and 50,000), respectively. Prior to 
analysis, mass calibration was performed for both ESI modes using the standard hermo Calmix solution.
he signals at 83.0604 m/z (2xACN + H) and 91.0037 m/z (2 x formate-H) were selected as lock masses for 
positive and negative mode, respectively. Data were recorded using the Xcalibur 2.1.0 sotware package (hermo 
Fisher Scientiic, Hemel Hempstead, UK).
Data Extraction. Data extraction was carried out using m/z Match sotware and IDEOM33. Metabolites 
were identiied to MSI levels 1 or 235 initially either according to exact mass ( < 3 ppm deviation) plus retention 
time matching to a standard or according to accurate mass. he extracted data was then modelled as described in 
supplementary information.
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